×
For best experience we recommend to activate Javascript in your browser.
Recombinant IL7RA (Lusvertikimab Biosimilar) antibody
The Human Monoclonal anti-IL7RA (Lusvertikimab Biosimilar) antibody is suitable to detect IL7RA (Lusvertikimab Biosimilar) in samples from Human. It has been validated for FACS, BLI, ELISA, Func and SPR.
Catalog No. ABIN7675781
$346.15
Plus shipping costs $50.00
1 mg ABIN7581529
100 μg ABIN7675781
1 mg ABIN7581529
100 μg ABIN7675781
Delivery in 10 to 12 Business Days
Quick Overview for Recombinant IL7RA (Lusvertikimab Biosimilar) antibody (ABIN7675781)
Target
IL7RA (Lusvertikimab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for IL7RA (Lusvertikimab Biosimilar) antibodies
Human
Clonality
All clonalities for IL7RA (Lusvertikimab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for IL7RA (Lusvertikimab Biosimilar) antibodies
This IL7RA (Lusvertikimab Biosimilar) antibody is un-conjugated
Application
Flow Cytometry (FACS), Bio-Layer Interferometry (BLI), ELISA, Functional Studies (Func), Surface Plasmon Resonance (SPR)
Product Details anti-IL7RA (Lusvertikimab Biosimilar) Antibody
(hide)
Expression System
CHO Cells
Purpose
Anti-IL-7Ra / CD127 Reference Antibody (lusvertikimab)
Characteristics
Anti-IL-7Ra / CD127 Reference Antibody (lusvertikimab) is expressed from CHO. The heavy chain type is huIgG4SP, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
Purity
>95 %
Isotype
IgG4 S228P
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Lyophilized
Concentration
1 mg/mL
Buffer
25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
Storage
4 °C,-80 °C
Storage Comment
+4°C,-80°C
Target Details for IL7RA (Lusvertikimab Biosimilar)
(hide)
Target
IL7RA (Lusvertikimab Biosimilar)
Alternative Name
IL-7Ra (Lusvertikimab Biosimilar)
Target Type
Biosimilar
Molecular Weight
145.5 kDa
UniProt
P16871
Recently viewed
(hide)
Chat with us , powered by LiveChat